TrialCancer2022

Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.

Pallawi Torka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.